Vaccines for human papillomavirus-associated anogenital disease and cervical cancer: practical and theoretical approaches

Bibliography

• TINDLE RW, FRAZER IH: Human papillomavirus infection, genital warts and cervical cancer: prospects for prophylactic and therapeutic vaccines. Exp. Opin. Invest. Drugs (1995) 4(9):783–797.
   Google Scholar
• BOSCH FX, MANOS MM, MUNOZ N et al.: Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J. Natl. Cancer Inst. (1995) 87(10:796–802.
   PubMedGoogle Scholar
• BOSCH FX, MUNOZ N, DE SANJOSE S: Human papillo-mavirus and other risk factors for cervical cancer. Biomed. Pharmacother. (1997) 51(6-7):268–275.
   PubMed Web of Science ®Google Scholar
• ZUR HAUSEN H: Papillomavirus in anogenital cancer: the dilemma of epidemiologic approaches. J. Natl. Cancer Inst. (1989) 81(22):1680–1682.
   PubMed Web of Science ®Google Scholar
• KOUTSKY LA, GALLOWAY DA, HOLMES KK: Epidemi-ology of genital human papillomavirus infection. Epidemiol. Rev. (1988) 10:122–163.
   PubMed Web of Science ®Google Scholar
• KIVIAT NB, KOUTSKY LA: Specific human papilloma-virus types as the causal agents of most cervical intraepithelial neoplasia: implications for current views and treatment. J. NatL Cancer Inst. (1993) 85(12):934–935.
   PubMed Web of Science ®Google Scholar
• SCHNEIDER A, KOUTSKY LA: Natural history and epidemiological features of genital HPV infection. IARC Sci. Publ. (1992) 119:25–52.
   PubMedGoogle Scholar
• ROGOZINSKI TT, JABLONSKA S, JARZABEK-CHORZELSKA M: Role of cell-mediated immunity in spontaneous regression of plane warts. Int. J. Dermatol (1988) 27(5):322–326.
   PubMed Web of Science ®Google Scholar
• UNGER ER, VERNON SD, LEE DR et al: Human papillo-mavirus type in anal epithelial lesions is influenced by human immunodeficiency virus. Arch. Pathol. Lab. Med. (1997) 121(8):820–824.
   PubMed Web of Science ®Google Scholar
• PALEFSKY JM, BARRASSO R: HPV infection and disease in men. ObsteL Gynecol Clin. N. Am. (1996) 23(4):895–916.
   PubMed Web of Science ®Google Scholar
• SUN XW, KUHN L, ELLERBROCK TV, CHIASSON MA, BUSH TJ, WRIGHT TC, JR: Human papillomavirus infection in women infected with the human immunodeficiency virus. New Engl. J. Med. (1997) 337(19):1343–1349.
   PubMed Web of Science ®Google Scholar
• PETRY KU, SCHEFFEL D, BODE U et al.: Cellular immunodeficiency enhances the progression of human papillomavirus-associated cervical lesions. Int. J. Cancer (1994) 57(6):836–840.
   PubMed Web of Science ®Google Scholar
• HO GY, BURK RD, FLEMING I, KLEIN RS: Risk of genital human papillomavirus infection in women with human immunodeficiency virus-induced immuno-suppression. Int. J. Cancer (1994) 56(6):788–792.
   PubMed Web of Science ®Google Scholar
• BRAUN L: Role of human immunodeficiency virus infection in the pathogenesis of human papillomavirus-associated cervical neoplasia. Am. J. Pathol (1994) 144(2):209–214.
   PubMed Web of Science ®Google Scholar
• TINDLE RW: Human papillomavirus vaccines for cervical cancer. Curr. Opin. Immunol. (1996) 8:643–650.
   PubMed Web of Science ®Google Scholar
• SELVAKUMAR R, BORENSTEIN LA, LIN YL, AHMED R, WETTSTEIN FO: Immunization with nonstructural proteins El and E2 of cottontail rabbit papillomavirus stimulates regression of virus-induced papillomas. J. Virol. (1995) 69(0:602–605.
   PubMed Web of Science ®Google Scholar
• WU TC: Immunology of the human papilloma virus in relation to cancer. Curr. Opin. ImmunoL (1994) 6(5):746–754.
   PubMed Web of Science ®Google Scholar
• CHRISTENSEN ND, CLADEL NM, REED CA: Postattach-ment neutralization of papillomaviruses by monoclonal and polyclonal antibodies. Virology (1995) 207:136–142.
   PubMed Web of Science ®Google Scholar
• ••Antibodies are able to neutralise papillomavirus infectionafter attachment of the virus to the cell surface. Post-attachment antibody neutralisation is a possible vaccine approach to HPV infection.
   Google Scholar
• RODEN RB, KIRNBAUER R, JENSON AB, LOWY DR, SCHILLER JT: Interaction of papillomaviruses with the cell surface. J. Vim]. (1994) 68(10:7260–7266.
   Google Scholar
• FRAZER IH, TINDLE RW: Cell immunity to Papillomavi-ruses. In: Papillomavirus reviews: Current research on papillomaviruses. Lacey C (Ed.) Leeds University Press, Leeds, UK (1996).
   Google Scholar
• SCHEFFNER M, HUIBREGTSE JM, VIERSTRA RD, HOWLEY PM: The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell (1993) 75:495–505.
   PubMed Web of Science ®Google Scholar
• SELBOS RJC, LEE MH, PLUNKETT BS, KESSIS TD, WILLIAMS BO, JACKS T: p52 G1 arrest involves pRB related proteins and is disrupted by the human papillomavirus 16 E7 oncoprotein. Proc. Natl. Acad. Sci. USA (1994) 91(12):5320–5325.
   PubMed Web of Science ®Google Scholar
• EVANDER M, FRAZER IH, PAYNE E, QI YM, HENGST K, MCMILLAN NA: Identification of the a6 integrin as a candidate receptor for papillomaviruses. Vim]. (1997) 71 (3):2449–2456.
   Google Scholar
• MCNEIL C: HPV vaccines for cervical cancer move toward clinic, encounter social issues. J. Natl. Cancer Inst. (1997) 89(22):1664–1666.
   PubMed Web of Science ®Google Scholar
• MCNEIL C: HPV vaccine treatment trials proliferate, diversify. J. Nail Cancer Inst. (1997) 89(4):280–281.
   PubMed Web of Science ®Google Scholar
• TOES RE, FELTKAMP MC, RESSING ME et al.: Cellular immunity against DNA tumour viruses: possibilities for peptide-based vaccines and immune escape. Biochem. Soc. Trans. (1995) 23(3):692–696.
   PubMed Web of Science ®Google Scholar
• TOES RE, BLOM RJ, OFFRINGA R, KAST WM, MELIEF CJ: Enhanced tumour outgrowth after peptide vaccina-tion. Functional deletion of tumour-specific CTL induced by peptide vaccination can lead to the inability to reject tumours. J. Immunol. (1996) 156(10):3911–3918.
   Google Scholar
• TOES RE, OFFRINGA R, BLOM RJ, MELIEF CJ, KAST WM: Peptide vaccination can lead to enhanced tumour growth through specific T-cell tolerance induction. Proc. Natl. Acad. Sci. USA (1996) 93(15):7855–7860.
   PubMed Web of Science ®Google Scholar
• FRAZER IH, TINDLE RW, FERNANDO GJP et al.: Safety and immunogenicity of HPV16 E7/Algammulin immuno-therapy for cervical cancer. In: Vaccines for human papillomavirus infection and disease. Tindle RW (Ed.), Laudes (Bioscience) (1999):105–119.
   Google Scholar
• DONNELLY JJ, ULMER JB, SHIVER JW, LIU MA: DNA Vaccines. Annu. Rev. Immunol (1997) 15:617–648.
   PubMed Web of Science ®Google Scholar
• •A comprehensive review of current DNA vaccine technology.
   Google Scholar
• MAHVI DM, SHEEHY MJ, YANG N: DNA cancer vaccines: a gene gun approach. Immunol. Cell Biol. (1997) 75:456–460.
   PubMed Web of Science ®Google Scholar
• ROBINSON HL: Nucleic acid vaccines: an overview.Vaccine (1997) 15(8):785–787.
   PubMed Web of Science ®Google Scholar
• CORR M, LEE DJ, CARSON DA, TIGHE H: Gene vaccina-tion with naked plasmid DNA: Mechanism of CTL priming. J. Exp. Med. (1996) 184:1555–1560.
   PubMed Web of Science ®Google Scholar
• DOE B, SELBY M, BARNETT S, BAENZIGER J, WALKER CM: Induction of cytotoxic T lymphocytes by intramus-cular immunization with plasmid DNA is facilitated by bone marrow-derived cells. Proc. Natl. Acad. Sci. USA (1996) 93:8578–8583.
   PubMed Web of Science ®Google Scholar
• KLINMAN DM, SECHLER JM, CONOVER J, GU M, ROSENBERG SA: Contribution of cells at the site of DNA vaccination to the generation of antigen- specific immunity and memory. J. Immunol. (1 9 9 8) 160:2388-2392.
   Google Scholar
• CONDON C, WATKINS SC, CELLUZZI CM, THOMPSON K,FALO LD: DNA- based immunization by in vivo transfection of dendritic cells. Nature Med. (1996) 2(10):1122–1128.
   PubMed Web of Science ®Google Scholar
• IWASAKI A, STIERNHOLM BJ, CHAN AK, BERINSTEIN NL,BARBER BH: Enhanced CTL responses mediated by plasmid DNA immunogens encoding costimulatory molecules and cytokines. J. Immunol. (1 99 7) 158:4591-4601.
   Google Scholar
• HORSPOOL JH, PERRIN PJ, WOODCOCK JB et al.: Nucleicacid vaccine-induced immune responses require CD28 costimulation and are regulated by CTLA4. J. Immunol (1998) 160:2706–2714.
   PubMed Web of Science ®Google Scholar
• CARBONE FR, KURTS C, BENNETT SR, MILLER JF, HEATHWR: Cross-presentation: a general mechanism for CTL immunity and tolerance. Immunol. Tod. (1998) 19(8)368–372.
   Google Scholar
• BARRY MA, JOHNSTON SA: Biological features ofgenetic immunization. Vaccine (1997) 15 (8):788–791.
   PubMed Web of Science ®Google Scholar
• LEE AH, SUH YS, SUNG JH, YANG SH, SUNG YC: Comparison of various expression plasmids for the induction of immune response by DNA immunization. Mol. Cells (1997) 7(0495–501.
   PubMed Web of Science ®Google Scholar
• NORMAN JA, HOBART P, MANTHORPE M, FELGNER P,WHEELER C: Development of improved vectors for DNA-based immunization and other gene therapy applications. Vaccine (1997) 15(8):801–803.
   PubMed Web of Science ®Google Scholar
• MONTGOMERY DL, SHIVER JW, LEANDER KR et al.: Heterologous and homologous protection against influenza A by DNA vaccination: optimization of DNA vectors. DNA Cell Biol. (1993) 12(9):777–783.
   PubMed Web of Science ®Google Scholar
• TOES RE, HOEBEN RC, VAN DER VOORT E et al.: Protec-tive anti-tumour immunity induced by vaccination with recombinant adenoviruses encoding multiple tumour-associated cytotoxic T lymphocyte epitopes in a string-of-beads fashion. Proc. Natl. Acad. Sci USA (1997) 94:14660–14665.
   Google Scholar
• JI H, CHANG EY, LIN KY, KURMAN RJ, PARDOLL DM, WUTC: Antigen- specific immunotherapy for murine lung metastatic tumours expressing human papillomavirus Type 16 E7 oncoprotein. Int. J. Cancer (1998) 78(1) :41–45.
   PubMed Web of Science ®Google Scholar
• RODRIGUEZ F, AN LL, HARKINS S et al.: DNA immuniza-tion with minigenes: Low frequency of memory cytotoxic T lymphocytes and inefficient antiviral protection are rectified by ubiquitination. J. Virol. (1998) 72(6):5174–5181.
   PubMed Web of Science ®Google Scholar
• RODRIGUEZ F, ZHANG J, WHITTON JL: DNA immuniza-tion: Ubiquitination of a viral protein enhances cytotoxic T-lymphocyte induction and antiviral protection but abrogates antibody induction. J. Vim]. (1997) 71(10:8497–8503.
   Google Scholar
• LIPFORD GB, SPARWASSER T, BAUER M et al.:Immunostimulatory DNA: sequence-dependent production of potentially harmful or useful cytokines. Eur. j Immunol. (1997) 27:3420–3426.
   PubMed Web of Science ®Google Scholar
• ROMAN M, MARTIN-OROZCO E, GOODMAN JS et al: Immunostimulatory DNA sequences function as T helper- 1-promoting adjuvants. Nature Med. (1997) 3 (8):849–854.
   PubMed Web of Science ®Google Scholar
• DE BRUIJN ML, GREENSTONE HL, VERMEULEN H, MELIEFCJ, LOWY DR,SCHILLER JT, KAST WM: Li-specific protec-tion from tumour challenge elicited by HPV16 virus-like particles. Virology (1998) 250(2)371–376.
   Google Scholar
• DONNELLY JJ, MARTINEZ D, JANSEN KU, ELLIS RW,MONTGOMERY DL, LIU MA: Protection against papillo-mavirus with a polynucleotide vaccine. J. Infect. Dis. (1996) i73(2):314–320.
   Google Scholar
• SUNDARAM P, TIGELAAR RE, BRANDSMA JL: Intracuta-neous vaccination of rabbits with the cottontail rabbit papillomavirus (CRPV) Li gene protects against virus challenge. Vaccine (1997) 15 (6–7)664–671.
   Google Scholar
• ••Demonstrated complete prophylactic protection againstCRPV challenge after DNA vaccination with a vector expressing CRPV-L1.
   Google Scholar
• SUNDARAM P, XIAO W, BRANDSMA JL: Particle-mediated delivery of recombinant expression vectors to rabbit skin induces high-titered polyclonal antisera (and circumvents purification of a protein immunogen). Nucleic Acids Res. (1996) 24 (7):1375–1377.
   PubMed Web of Science ®Google Scholar
• SUNDARAM P, TIGELAAR RE, XIAO W, BRANDSMA JL: Intracutaneous vaccination of rabbits with the E6 gene of cottontail rabbit papillomavirus provides partial protection against virus challenge. Vaccine (1998) 16(6):613–623.
   PubMed Web of Science ®Google Scholar
• TINDLE RW, FRAZER IH: Immune response to humanpapillomaviruses and the prospects for human papillomavirus-specific immunization. Curr. Top. Microbiol. Immunol. (1994) 186:217–253.
   PubMedGoogle Scholar
• ZHOU J, SUN XY, STENZEL DJ, FRAZER IH: Expression of vaccinia recombinant HPV 16 Li and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology (1991) 185 (1):251–257.
   PubMed Web of Science ®Google Scholar
• ••An early report on the in vitro production of empty HPV 16L1 /L2 virus-like particles.
   Google Scholar
• KIRNBAUER R, BOOY F, CHENG N, LOWY DR, SCHILLERJT: Papillomavirus Li major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc. Natl. Acad. Sci. USA (1992) 89(24):12180–12184.
   PubMed Web of Science ®Google Scholar
• ROSE RC, BONNEZ W, REICHMAN RC, GARCEA RL: Expression of human papillomavirus Type 11 Li protein in insect cells: in vivo and in vitro assembly of virus like particles. J. Vim]. (1993) 67(4):1936–1944.
   Web of Science ®Google Scholar
• HAGENSEE ME, YAEGASHI N, GALLOWAY DA: Self-assembly of human papillomavirus Type 1 capsids by expression of the Li protein alone or by coexpression of the Li and L2 capsid proteins. J. Virol. (1993) 67(1):315–322.
   PubMed Web of Science ®Google Scholar
• KIRNBAUER R, TAUB J, GREENSTONE HL et al. Efficient self-assembly of human papillomavirus Type 16 Li and Li-L2 into virus-like particles. J. Virol. (1993) 67(12)6929–6936.
   Google Scholar
• CHRISTENSEN ND, KREIDER JW, KAN NC, DIANGELO SL:The open reading frame L2 of cottontail rabbit papillo-mavirus contains antibody-inducing neutralizing epitopes. Virology (1991) 181 (2)572–579.
   Google Scholar
• IN YL, BORENSTEIN LA, SELVAKUMAR R, AHMED R, WETTSTEIN FO: Effective vaccination against papilloma development by immunization with Li or L2 structural protein of cottontail rabbit papilloma-virus. Virology (1992) i87(2):612–619.
   Google Scholar
• RODEN RB, GREENSTONE HL, KIRNBAUER R et al.: Invitro generation and type-specific neutralization of a human papillomavirus Type 16 virion pseudotype. J. Virol. (1996) 70(9):5875–5883.
   PubMed Web of Science ®Google Scholar
• BALMELLI C, RODEN R, POTTS A et al. Nasal immuniza- tion of mice with human papillomavirus Type 16 virus-like particles elicits neutralizing antibodies in mucosal secretions. J. Virol (1998) 72(10):8220–8229.
   PubMed Web of Science ®Google Scholar
• CHRISTENSEN ND, HOPFL R, DIANGELO SL et al.: Assembled baculovirus- expressed human papilloma-virus Type 11 Li capsid protein virus-like particles are recognized by neutralizing monoclonal antibodies and induce high titres of neutralizing antibodies. J. Gen. Virol (1994) 75(9):2271–2276.
   PubMed Web of Science ®Google Scholar
• WHITE WI, WILSON SD, BONNEZ W, ROSE RC, KOENIG S, SUZICH JA: In vitro infection and type-restricted antibody-mediated neutralization of authentic human papillomavirus Type 16. J. Vim]. (1998) 72(2):959–964.
   Web of Science ®Google Scholar
• LOWE RS, BROWN DR, BRYAN JT et al.: Human papillo-mavirus Type 11 (HPV-11) neutralizing antibodies in the serum and genital mucosal secretions of African green monkeys immunized with HPV-11 virus-like particles expressed in yeast. J. Infect. Dis. (1997) 176(5):1141–1145.
   PubMed Web of Science ®Google Scholar
• NARDELLI-HAEFLIGER D, RODEN RB, BENYACOUB J etal.: Human papillomavirus Type 16 virus-like particles expressed in attenuated Salmonella typhimurium elicit mucosal and systemic neutralizing antibodies in mice. Infect. Immun. (1997) 65(8):3328–3336.
   Google Scholar
• HOFMANN KJ, NEEPER MP, MARKUS HZ, BROWN DR, MULLER M, JANSEN KU: Sequence conservation within the major capsid protein of human papillomavirus (HPV) Type 18 and formation of HPV-18 virus-like particles in Saccharomyces cerevisiae. J. Gen. Virol (1996) 77(3):465–468.
   PubMed Web of Science ®Google Scholar
• GREENSTONE HL, NIELAND JD, DE VISSER KE et al.: Chimeric papillomavirus virus-like particles elicit antitumour immunity against the E7 oncoprotein in an HPV16 tumour model. Proc. Natl. Acad. Sci. USA (1998) 95(4):1800–1805.
   Google Scholar
• ••Immunisation with HPV16 L1/L2/HPV16 E7 chimeric VLPsprotected against challenge with tumour cells expressing HPV 16 E7 in a class I-restricted manner. This response was also induced in the absence of adjuvant. Demonstrates the potential of chimeric VLPs as therapeutic HPV vaccines.
   Google Scholar
• PENG S, FRAZER IH, FERNANDO GJ, ZHOU J: Papilloma- virus virus-like particles can deliver defined CTL epitopes to the MHC class I pathway. Virology (1998) 240:147–157.
   PubMed Web of Science ®Google Scholar
• MULLER M, ZHOU J, REED TD et al: Chimeric papilloma-virus- like particles. Virology (1997) 234:93–111.
   PubMed Web of Science ®Google Scholar
• HOFMANN KJ, COOK JC, JOYCE JG et al.: Sequence determination of human papillomavirus Type 6a and assembly of virus-like particles in Saccharomyces cerevisiae. Virology (1995) 209:506–518.
   PubMed Web of Science ®Google Scholar
• JANSEN KU, ROSOLOWSKY M, SCHULTZ LD et al.: Vaccination with yeast- expressed cottontail rabbit papillomavirus (CRPV) virus-like particles protects rabbits from CRPV-induced papilloma formation. Vaccine (1995) 13(16):1509–1514.
   PubMed Web of Science ®Google Scholar
• BREITBURD F, KIRNBAUER R, HUBBERT NL et al.:Immunization with virus like particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J. Virol. (1995) 69(6)3959–3963.
   Google Scholar
• SUZICH JA, GHIM SJ, PALMER HILL FJ et al.: Systemicimmunization with papillomavirus Li protein completely prevents the development of viral mucosal papillomas. Proc. Natl. Acad. Sci. USA (1995) 92 (25):11553–11557.
   Google Scholar
• KIRNBAUER R, CHANDRACHUD LM, O'NEIL BW et al.:Virus-like particles of bovine papillomavirus Type 4 in prophylactic and therapeutic immunization. Virology (1996) 219(0:37–44.
   Google Scholar
• CHRISTENSEN ND, REED CA, CLADEL NM, HAN R, KREIDER JW: Immunization with virus like particles induces long-term protection of rabbits against challenge with cottontail rabbit papillomavirus. J. Vim]: (1996) 70(2):960–965.
   Web of Science ®Google Scholar
• ••Rabbits immunised with CRPV-L1 VLPs were completelyprotected against virus challenge. This protection persisted for over one year.
   Google Scholar
• KAWANA K, YOSHIKAWA H, TAKETANI Y, YOSHIIKE K,KANDA T: In vitro construction of pseudovirions of human papillomavirus Type 16: Incorporation of plasmid DNA into reassembled Li/L2 capsids. J. Virol. (1998) 72(12):10298–10300.
   PubMed Web of Science ®Google Scholar
• TOUZE A, COURSAGET P: In vitro gene transfer usinghuman papillomavirus- like particles. Nucleic Acids Res. (1998) 26(5):1317–1323.
   PubMed Web of Science ®Google Scholar
• •HPV VLPs are capable of carrying foreign DNA. Loading of the DNA can be performed after purification of the VLP. These DNA carrying VLPs have been demonstrated to transfer DNA to cells in vitro.
   Google Scholar
• WILSON JM: Adenoviruses as gene-delivery vehicles. NEngl. J. Med. (1996) 334(18):1185–1187.
   PubMed Web of Science ®Google Scholar
• RANDRIANARISON-JEWTOUKOFF V, PERRICAUDET M: Recombinant adenoviruses as vaccines. Biologicals (1995) 23:145–157.
   PubMed Web of Science ®Google Scholar
• RAGOT T, FINERTY S, WATKINS PE, PERRICAUDET M, MORGAN AJ: Replication-defective recombinant adenovirus expressing the Epstein-Barr virus (EBV) envelope glycoprotein gp340/220 induces protective immunity against EBV-induced lymphomas in the cottontop tamarin. J. Gen. Vim]. (1993) 74(3)501–507.
   Google Scholar
• MCDERMOTT MR, GRAHAM FL, HANKE T, JOHNSON DC: Protection of mice against lethal challenge with herpes simplex virus by vaccination with an adenovirus vector expressing HSV glycoprotein B. Virology (1989) 169(0:244–247.
   PubMed Web of Science ®Google Scholar
• SONG W, KONG HL, CARPENTER H et al.: Dendritic cells genetically modified with an adenovirus vector encoding the cDNA for a model antigen induce protec-tive and therapeutic antitumour immunity. J. Exp. Med. (1997) 186(8):1247–1256.
   PubMed Web of Science ®Google Scholar
• LI W, BERENCSI K, BASAK S et al. Human colorectal cancer (CRC) antigen C017-1A/GA733 encoded by adenovirus inhibits growth of established CRC cells in mice. J. Immunol. (1997) 159(2):763–769.
   PubMed Web of Science ®Google Scholar
• BROSSART P, GOLDRATH AW, BUTZ EA, MARTIN S, BEVAN MJ: Virus- mediated delivery of antigenic epitopes into dendritic cells as a means to induce CTL. Immunol. (1997) 158(7):3270–3276.
   Web of Science ®Google Scholar
• MACKETT M, SMITH GL, MOSS B: Vaccinia virus: a selectable eukaryotic cloning and expression vector. Proc. Natl. Acad. ScL USA (1982) 79(23):7415–7419.
   PubMed Web of Science ®Google Scholar
• GAO L, CHAIN B, SINCLAIR C et al.: Immune response to human papillomavirus Type 16 E6 gene in a live vaccinia vector. J. Gen. Vim]. (1994) 75(1):157–164.
   PubMed Web of Science ®Google Scholar
• BORYSIEWICZ LK, FIANDER A, NIMAKO M et al.: A recombinant vaccinia virus encoding human papillo-mavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet (1996) 347 (9014) :1523–1527.
   PubMed Web of Science ®Google Scholar
• ••Demonstrated the clinical safety and immunogenicity of avaccinia virus vector expressing HPV 16 and 18 E6 and E7 in cervical cancer patients.
   Google Scholar
• ZHU X, TOMMASINO M, VOUSDEN K et al.: Both immuni- zation with protein and recombinant vaccinia virus can stimulate CTL specific for the E7 protein of human papilloma virus 16 in H-2d mice. Scand. J. Immunol (1995) 42(5):557–563.
   PubMed Web of Science ®Google Scholar
• BOURSNELL ME, RUTHERFORD E, HICKLING JK et al. Construction and characterisation of a recombinant vaccinia virus expressing human papillomavirus proteins for immunotherapy of cervical cancer. Vaccine (1996) i4(16):1485–1494.
   Google Scholar
• NINDL I, GISSMANN L, FISHER SG, BRIBIESCA LB,BERUMEN J, MULLER M: The E7 protein of human papillomavirus (HPV) Type 16 expressed by recombi-nant vaccinia virus can be used for detection of antibodies in sera from cervical cancer patients. J. Virol. Methods (1996) 62(0:81–85.
   PubMed Web of Science ®Google Scholar
• MENEGUZZI G, CERNI C, KIENY MP, LATHER: Immuniza-tion against human papillomavirus Type 16 tumour cells with recombinant vaccinia viruses expressing E6 and E7. Virology (1991) 181:62–69.
   PubMed Web of Science ®Google Scholar
• ZHOU JA, MCINDOE A, DAVIES H, SUN XY, CRAWFORD L:The induction of cytotoxic T-lymphocyte precursor cells by recombinant vaccinia virus expressing human papillomavirus Type 16 Li. Virology (1 9 9 1) 181 (1):203–210.
   Google Scholar
• HAGENSEE ME, CARTER JJ, WIPF GC, GALLOWAY DA:Immunization of mice with HPV vaccinia virus recombinants generates serum IgG, IgM, and mucosal IgA antibodies. Virology (1995) 206 (1):174–182.
   PubMed Web of Science ®Google Scholar
• GIRARD M, ALTMEYER R, VAN DER WERF S, WYCHOWSKI C, MARTIN A: The use of Picornaviruses as vectors for the engineering of live recombinant vaccines. Biologi-cals (1995) 23:165–169.
   PubMed Web of Science ®Google Scholar
• JENKINS 0, CASON J, BURKE KL, LUNNEY D, GILLEN A,PATEL D, MCCANCE DJ, ALMOND JW: An antigen chimera of poliovirus induces antibodies against human papillomavirus Type 16. J. Virol. (1990) 64 (3):1201–1206.
   PubMed Web of Science ®Google Scholar
• GOOSSENS PL, MONTIXI C, SARON MF, RODRIGUEZ M,ZAVALA F, MILON G: Listeria monocytogenes: A Live Vector Able to Deliver Heterologous Protein Within the Cytosol and to Drive a CD8 Dependent T Cell Response. Biologicals (1995) 23:135–143.
   PubMed Web of Science ®Google Scholar
• IKONOMIDIS G, PATERSON Y, KOS FJ, PORTNOY DA: Delivery of a viral antigen to the Class I processing and presentation pathway by Listeria monocytogenes. J. Exp. Med. (1994) 180:2209–2218.
   PubMed Web of Science ®Google Scholar
• GOOSSENS PL, MILON G, COSSART P, SARON MF: Attenu-ated Listeria monocytogenes as a live vector for the induction of CD8+ T cells in viva a study with the nucleoprotein of the lymphocytic choriomeningitis virus. Int. Immunol. (1995) 7(5):797–805.
   PubMed Web of Science ®Google Scholar
• PAGLIA P, ARIOLI I, FRAHM N, CHAKRABORTY T, COLOMBO MP, GUZMAN CA: The defined attenuated Listeria monocytogenes delta mpl2 mutant is an effective oral vaccine carrier to trigger a long-lasting immune response against a mouse fibrosarcoma. Eur. Immunol (1997) 27(6):1570–1575.
   PubMed Web of Science ®Google Scholar
• JENSEN ER, SELVAKUMAR R, SHEN H, AHMED R, WETTSTEIN FO, MILLER JF: Recombinant Listeria monocytogenes vaccination eliminates papillomavi-rus- induced tumours and prevents papilloma formation from viral DNA. J. Virol. (1 9 9 7) 71(10:8467-8474.
   Google Scholar
• TURNER SJ, CARBONE FR, STRUGNELL RA: Salmonella typhimurium aroA aroD mutants expressing a foreign recombinant protein induce specific major histocom-patibility complex class-I restricted cytotoxic T lymphocytes in mice. Infect. Immun. (1 9 9 3) 61(12)5374–5380.
   Google Scholar
• HARDING CV, PFEIFER JD: Antigen expressed by Salmonella typhimurium is processed for class I major histocompatibility complex presentation by macrophages but not infected epithelial cells. Immunology (1994) 83 (4):670–674.
   PubMed Web of Science ®Google Scholar
• DOUGAN G, HORMAECHE CE, MASKELL DJ: Live oral Salmonella vaccines: potential use of attenuated strains as carriers of heterologous antigens to the immune system. Parasite Immunol. (1987) 9(2):151–160.
   PubMed Web of Science ®Google Scholar
• LONDONO P, CHATFIELD SN, TINDLE RW et al.: Immuni-zation of mice using Salmonella typhimurium expressing human papillomavirus Type 16 E7 epitopes inserted into hepatitis B virus core antigen. Vaccine (1996) 14(6):545–552.
   PubMed Web of Science ®Google Scholar
• HOPKINS S, KRAEHENBUHL JP, SCHODEL F et al.: A recombinant Salmonella typhimurium vaccine induces local immunity by four different routes of immunization. Infect. Immun. (1995) 63 (9):3279–3286.
   PubMed Web of Science ®Google Scholar
• STRUGNELL RA, DOUGAN G, CHATFIELD SN et al.: Characterization of a Salmonella typhimurium aro vaccine strain expressing the P.69 antigen of Bordetella pertussis. Infect. Immun. (1 9 9 2) 60:3994-4002.
   Google Scholar
• GICQUEL B: BCG as a vector for the construction of multivalent recombinant vaccines. Biologicals (1995) 23:113–118.
   PubMed Web of Science ®Google Scholar
• FLYNN JL, GOLDSTEIN MM, TRIEBOLD KJ, KOLLER B, BLOOM BR: Major histocompatibility complex class I-restricted T cells are required for resistance to Mycobacterium tuberculosis infection. Proc. Natl. Acad. ScL USA (1992) 89(24):12013–12017.
   PubMed Web of Science ®Google Scholar
• ALDOVINI A, YOUNG RA: Humoral and cell-mediated immune responses to live recombinant BCG-HIV vaccines. Nature (1991) 351:479–482.
   PubMed Web of Science ®Google Scholar
• LAGRANDERIE M, LO-MAN R, DERIAUD E et al: Genetic control of antibody responses induced by recombi-nant Mycobacterium bovis BCG expressing a foreign antigen. Infect. Immun. (1997) 65(8):3057–3064.
   PubMed Web of Science ®Google Scholar
• LAGRANDERIE M, BALAZUC AM, GICQUEL B, GHEORGHIU M: Oral immunization with recombinant Mycobacterium bovis BCG simian immunodeficiency virus nef induces local and systemic cytotoxic T-lymphocyte responses in mice. J. Virol. (1997) 71(3)2303–2309.
   Google Scholar
• WINTER N, LAGRANDERIE M, RAUZIER J et al.: Expres-sion of heterologous genes in Mycobacterium bovis BCG: induction of a cellular response againstHW-1 Nef protein. Gene (1991) 109(0:47–54.
   PubMed Web of Science ®Google Scholar
• MURRAY PJ, ALDOVINI A, YOUNG RA: Manipulation and potentiation of antimycobacterial immunity using recombinant bacille Calmette-Guerin strains that secrete cytokines. Proc. Natl. Acad. ScL USA (1996) 93 (2):934–939.
   PubMed Web of Science ®Google Scholar
• OSSEVOORT MA, FELTKAMP MC, VAN VEEN KJ, MELIEF CJ, KAST WM: Dendritic cells as carriers for a cytotoxic T-lymphocyte epitope-based peptide vaccine in protection against a human papillomavirus Type 16-induced tumour. J. Immunother. (1995) 18(2)86–94.
   Google Scholar
• •First demonstration of protection against a HPV16 transformed tumour cell line, by a single immunisation with HPV 16 E7 (49–57) peptide loaded dendritic cells.
   Google Scholar
• DE BRUIJN ML, SCHUURHUIS DH, VIERBOOM MP et al.: Immunization with human papillomavirus Type 16 (HPV16) oncoprotein- loaded dendritic cells as well as protein in adjuvant induces MHC class I-restricted protection to HPV16-induced tumour cells. Cancer Res. (1998) 58(4):724–731.
   PubMed Web of Science ®Google Scholar
• ••Demonstrated that DC pulsed with HPV 16 E7 proteininduced E7 specific CTLs in vivo. This CTL generation was associated with tumour protection.
   Google Scholar
• MURPHY G, TJOA B, RAGDE H, KENNY G, BOYNTON A: Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen. Prostate (1996) 29(6):371–380.
   PubMed Web of Science ®Google Scholar
• HSU FJ, BENIKE C, FAGNONI F et al.: Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nature Med. (1996) 2(1):52–58.
   PubMed Web of Science ®Google Scholar
• •A pilot clinical study immunising four B-cell lymphoma patients with antigen pulsed dendritic cells. Clinical responses induced complete tumour regression in one individual.
   Google Scholar
• MAYORDOMO JI, ZORINA T, STORKUS WJ et al.: Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nature Med. (1995) 1(12):1297–1302.
   PubMed Web of Science ®Google Scholar
• ROUSE RJ, NAIR SK, LYDY SL, BOWEN JC, ROUSE BT: Induction in vitro of primary cytotoxic T-lymphocyte responses with DNA encoding herpes simplex virus proteins. J. Virol. (1994) 68(9):5685–5689.
   PubMed Web of Science ®Google Scholar
• TUTING T, DELEO AB, LOTZE MT, STORKUS WJ: Geneti-cally modified bone marrow-derived dendritic cells expressing tumour-associated viral or 'self antigens induce antitumour immunity in vivo. Eur. J. Immunol. (1997) 27(10):2702–2707.
   PubMed Web of Science ®Google Scholar
• WAN Y, BRAMSON J, CARTER R, GRAHAM F, GAULDIE J: Dendritic cells transduced with an adenoviral vector encoding a model tumour-associated antigen for tumour vaccination. Hum. Gene Ther. (1997) 8(10:1355–1363.
   PubMed Web of Science ®Google Scholar
• KIM CJ, PREVETTE T, CORMIER J et al.: Dendritic cells infected with poxviruses encoding MART-1/Melan A sensitize T lymphocytes in vitro. J. Immunother. (1997) 20(4)276–286.
   Google Scholar
• REEVES ME, ROYAL RE, LAM JS, ROSENBERG SA, HWU P: Retroviral transduction of human dendritic cells with a tumour-associated antigen gene. Cancer Res. (1996) 56(24)5672–5677.
   Google Scholar
• SPECHT JM, WANG G, DO MT et al: Dendritic cells retrovirally transduced with a model antigen gene are therapeutically effective against established pulmonary metastases. J. Exp. Med. (1997) 186(8):1213–1221.
   PubMed Web of Science ®Google Scholar
• PULENDRAN B, LINGAPPA J, KENNEDY MK et al.: Developmental pathways of dendritic cells in vivo: distinct function, phenotype, and localization of dendritic cell subsets in FLT3 ligand- treated mice. J. Immunol. (1997) 159(5):2222–2231.
   PubMed Web of Science ®Google Scholar
• TAO MH, LEVY R: Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma. Nature (1993) 362:755–758.
   PubMed Web of Science ®Google Scholar
• THOMSON SA, SHERRITT MA, MEDVECZKY J et al.: Delivery of multiple CD8 cytotoxic T cell epitopes by DNA vaccination. J. Immunol. (1998) 160:1717–1723.
   PubMed Web of Science ®Google Scholar
• THOMSON SA, KHANNA R, GARDNER J et al.: Minimal epitopes expressed in a recombinant polyepitope protein are processed and presented to CD8+ cytotoxic T cells: Implications for vaccine design. Proc. Natl. Acad. Sci. USA (1995) 92:5845–5849.
   PubMed Web of Science ®Google Scholar
• ••A polytope of 9 CTL epitopes with differing MHC ClassI-restriction, linked without flanking sequences, was correctly processed and presented for all 9 epitopes. Implications for generation of human papillomavirus vaccines for outbred human populations.
   Google Scholar
• LO-MAN R, LANGEVELD JP, MARTINEAU P, HOFNUNG M, MELOEN RH, LECLERC C: Immunodominance does not result from peptide competition for MHC class II presentation. J. Immunol. (1998) 160:1759–1766.
   PubMed Web of Science ®Google Scholar
• ••Demonstrates (for MHC Class II-restriction), that processingand presentation of epitopes within a polytope are not influenced by immunological dominance. Robert W Tindlet & Michael D Street Author for correspondence Sir Albert Sakzewski Virus Research Centre, Royal Children's Hospital, Herston Road, Herston, QLD, 4029, Australia Tel.: +61 7 3253 8716; Fax: +61 7 3253 1401; Email: [email protected]
   Google Scholar